Bred by the University of Adelaide at its Waite Institute, WI4896 has been named Leabrook having passed stage 1 malt accreditation in March. It will become an accredited malting variety in March 2020 if it passes Stage 2 this year.
GPN Vaccines, a vaccine development company focussed on the prevention of diseases caused by the world’s foremost bacterial pathogen, Streptococcus pneumoniae, has raised AUD$1.1 million (USD$0.8 million) towards development of its proprietary vaccine, Gamma-PNTM.
Research on a bacterial toxin first discovered in Adelaide has led to the development a new blood test for the early diagnosis of ovarian cancer - a disease which kills over 1000 Australian women and 150,000 globally each year.
Congratulations to the recipients of the 2018 Commercial Accelerator Scheme (CAS)
A novel Australian invention that allows neurosurgeons to illuminate parts of the brain and avoid devastating complications during a biopsy has been trialled in humans for the first time.
Cutting edge 3D metal printers are keeping South Australian advanced manufacturing in the game with the innovative technology already attracting some 100 companies to the Playford region of Adelaide.
Due date: November 2, 2018
The Adelaide Enterprise Intellectual Property (IP) induction course is designed to help you protect your ideas by giving you insight into the legal side of intellectual property. It provides an overview of intellectual property and how you can protect your ideas, as well as on aspects such as trade marks, copyright and patents.
Adelaide’s Carina Biotech has been awarded a $2.1 million Cooperative Research Centre Project (CRC-P) Program grant to continue its groundbreaking work developing new cell therapies to treat solid, pediatric and rare cancers.
Microbiotica collaborates with University of Adelaide to develop a novel microbial therapy for ulcerative colitis
"Cambridge, UK, 18 June 2018 – Microbiotica, a leading player in microbiome-based therapeutics, today announced that it has entered into an agreement with University of Adelaide as part of its programme to develop a defined bacterial product for ulcerative colitis (UC). Financial details have not been disclosed.